Chester County News and Community Website
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company, recently made a significant stride in its quest for innovative vision restoration solutions. The company announced that the first patient …
Ocugen’s Pioneering Gene Therapy OCU410 Takes Major Step Forward in Clinical Trials Read More
BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) has recently announced the completion of the last patient visit in its phase III study of buntanetap, a leading candidate for treating …
Annovis Bio Finalizes Phase III Study of Buntanetap in Early Parkinson’s Treatment, Awaits Topline Data Read More
CHESTERBROOK, PA — Biopharmaceutical company Trevena, Inc. (Nasdaq: TRVN), known for its innovative work in developing and commercializing novel medicines for central nervous system disorders, recently announced the acceptance of …
Trevena’s Investigator-Led RELIEVE Study Accepted for Presentation at 2024 American Burn Association Meeting Read More BERWYN, PA — Chester County-based biopharmaceutical company Annovis Bio, Inc. (NYSE: ANVS) announced this week that its phase II/III study of buntanetap, a potential treatment for Alzheimer’s Disease (AD), has …
Annovis Bio’s Phase II/III Study of Buntanetap Exceeds Full Enrollment Read More
BERWYN, PA — Chester County-based biotech company, Panavance Therapeutics Inc., has announced the recent publication of positive data in the International Journal of Molecular Sciences about the anti-tumor activity of …
Panavance Therapeutics’ Cancer Drug Misetionamide Shows Promising Results in Melanoma Treatment Read More
WAYNE, PA — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, has announced the first patient enrollment in the ACCESS-MANTA™ Registry. This international, multicenter, prospective, observational, single-arm …
Teleflex Launches ACCESS-MANTA Registry to Evaluate MANTA Vascular Closure Device Read More WAYNE, PA — A groundbreaking study published in the Nature journal Prostate Cancer and Prostatic Diseases has bolstered the position of the UroLift™ System as the leading minimally invasive surgical …
New Study Reinforces UroLift™ System as Gold Standard Treatment for Enlarged Prostate Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) this week announced disappointing top-line results from a Phase 2b study of zunsemetinib (ATI-450) in patients with moderate to severe rheumatoid arthritis …
Aclaris Therapeutics Halts Development of Rheumatoid Arthritis Drug After Phase 2b Study Misses Primary Endpoint Read More MALVERN, PA — Biopharmaceutical company Ocugen, Inc. (NASDAQ: OCGN) has announced the commencement of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA), a gene therapy candidate being developed to …
Ocugen Initiates Phase 1/2 GARDian Clinical Trial for Stargardt Disease Therapy Read More BERWYN, PA — In a recent breakthrough, Annovis Bio (NYSE: ANVS), a biopharmaceutical company, has successfully performed measurements of critical biomarkers in the plasma of Parkinson’s disease patients. Utilizing buntanetap, …
Annovis Bio’s Buntanetap Demonstrates Potential to Lower Key Biomarkers in Parkinson’s Disease Read More